All In Biotech

NDA 208254 · Alcon Labs INC

Rhopressa

Netarsudil Mesylate · Ophthalmic

Novel

Last checked: Nov 20, 2026Latest source record: Sep 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 18, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

43

14 Phase 3, 8 recruiting

FAERS reports

1,971

434 serious, 63 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 20, 2026.

RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. RHOPRESSA ® is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 )

Mechanism: Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork. The exact mechanism is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 18, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • RHOPRESSA · NETARSUDIL MESYLATE EQ 0.02% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Netarsudil" as an intervention, any sponsor and status, largest first.

All 43 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • conjunctival hyperaemia246
  • vision blurred165
  • ocular hyperaemia162
  • off label use158
  • eye pain149
  • eye irritation123
  • product dose omission issue98
  • corneal oedema95
  • intraocular pressure increased95
  • lacrimation increased94
  • visual acuity reduced89
  • drug ineffective79

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
2018145
2019470
2020253
2021111
2022137
2023244
2024210
2025227
2026173

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rhopressa (Netarsudil Mesylate)

2024 spending

$168M

Beneficiaries

89,311

353,836 claims

Per beneficiary

$1,882

$126.18 per unit

View as table
YearSpending
2020$109,355,175
2021$134,396,762
2022$160,954,924
2023$174,888,744
2024$168,045,637

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 34 on PubMed

Sponsor: Alcon Labs INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.